Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles
-
By
-
Allison DeAngelis
-
Elaine Chen
-
Adam Feuerstein
-
May 7, 2026
-
Clinical Scorecard: Seaport Therapeutics' IPO Success, Obesity Medication Rivalries, and Challenges Faced by Makary
At a Glance
| Category | Detail |
|---|
| Condition | Obesity |
| Key Mechanisms | Pharmaceutical interventions targeting weight loss |
| Target Population | Individuals with obesity |
| Care Setting | Outpatient and clinical research settings |
Key Highlights
- Seaport Therapeutics successfully completed its IPO
- Eli Lilly and Novo Nordisk are competing in the obesity medication market
- Cytokinetics achieved a Phase 3 study win
- FDA Commissioner Marty Makary faces challenges
- This marks the 400th episode of 'The Readout LOUD'
Guideline-Based Recommendations
Diagnosis
- Assess body mass index (BMI) for obesity classification
Management
- Consider pharmacotherapy for patients with BMI ≥30 or BMI ≥27 with comorbidities
Monitoring & Follow-up
- Regularly evaluate weight loss progress and side effects of medications
Risks
- Monitor for potential adverse effects associated with obesity medications
Patient & Prescribing Data
Adults with obesity or overweight with related health issues
Emerging therapies are being developed to enhance weight loss outcomes
Clinical Best Practices
- Incorporate lifestyle modifications alongside pharmacotherapy
- Engage in shared decision-making with patients regarding treatment options
- Stay updated on the latest clinical trials and emerging therapies
References
